World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 3.454
Year - 2023
Volume: 2; Issue: 5
Page: 123-134

JOURNEY FROM SYMPTOM RECOGNITION TO SCREENING APPROACHES: A LITERATURE REVIEW ON DIABETES

Mustafa H. Ghazi[1*], Riyadh Abdulkareem[2] and Ayat Adnan Abbas[3]

[1]College of Nursing, Al-Muthanna University; Iraq.
[2]University of Anbar / Chemical, Biological and Radiological Safety Security Section, Al:Anbar, Iraq.
[3]Biotechnology Research Center AL-Nahrain University.

Article Received: 20 July 2023 || Article Revised: 08 September 2023 || Article Accepted: 29 September 2023

Corresponding Author: Mustafa H. Ghazi
College of Nursing, Al-Muthanna University; Iraq.

ABSTRACT
This literature review aims to assess the diagnosis of diabetes, focusing on the significance of early identification and a comprehensive examination of the challenges associated with symptom-based diagnosis. The review explores multiple screening methods: the glycated hemoglobin (HbA1c) test, random plasma glucose test, oral glucose tolerance test, and fasting plasma glucose (FPG) test. Furthermore, it analyzes the potential enhancements in screening accuracy that can be achieved through advancements in diagnostic technologies, including continuous glucose monitoring (CGM), point-of-care testing (POCT), artificial intelligence (AI), machine learning (ML), and wearable devices. The analysis also highlights the obstacles encountered in diabetes diagnosis, such as the unpredictability of symptoms and limited accessibility to healthcare providers. As a result, this study puts forth prospective remedies, encompassing the reinforcement of educational and awareness campaigns, enhancement of healthcare availability, formulation of ethnicity-specific algorithms, advocacy for data exchange and standardization, integration of machine learning and artificial intelligence (ML/AI) into clinical settings, and adoption of longitudinal monitoring approaches. Ultimately, the manuscript concludes by underscoring the pivotal role played by early detection in proficiently managing diabetes and averting complications while simultaneously accentuating the necessity for additional research to validate these technologies and augment diagnostic capacities.

1. INTRODUCTION

Diabetes is a chronic metabolic disorder characterized by the body's inability to regulate blood glucose levels effectively. This pathological condition presents hyperglycemia, which arises from either deficient insulin secretion or impaired insulin functionality. Insulin, a hormone synthesized by the pancreas, plays a crucial role in facilitating the entry of glucose into cells for energy metabolism. Insufficient insulin production or impaired utilization leads to the accumulation of glucose in the circulatory system, resulting in many health complications.[1,2]

The classification of diabetes comprises three main types: type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 1 diabetes is an autoimmune disease wherein the immune system erroneously attacks and destroys the insulin-producing cells in the pancreas, resulting in minimal to no insulin production. Consequently, individuals with type 1 diabetes necessitate insulin injections or an insulin pump to manage their blood sugar levels.[3]

On the other hand, type 2 diabetes represents the most prevalent form and typically manifests later in life. It arises when the body develops insulin resistance or fails to produce sufficient quantities to meet its requirements.[4] Lifestyle factors, including obesity, sedentary behavior, and poor dietary habits, are closely associated with type 2 diabetes. Although lifestyle modifications such as adopting a healthy diet, engaging in regular exercise, and, if necessary, medication can often manage type 2 diabetes, some individuals may require insulin therapy.

Gestational diabetes occurs during pregnancy and generally resolves after childbirth. Hormonal changes affecting insulin sensitivity contribute to elevated blood sugar levels in this condition. However, women with gestational diabetes face an increased risk of developing type 2 diabetes later in life.[5]

The prevalence of diabetes has experienced a steady increase over recent decades, thereby emerging as a significant global health concern. According to the International Diabetes Federation (IDF), approximately 463 million adults aged 20-79 had diabetes worldwide in 2021. If current trends persist, this figure will rise to 700 million by 2045.[6]

The impact of diabetes transcends individual health and exerts a substantial burden on healthcare systems and economies due to the expenses associated with managing the condition and its complications. Diabetes is linked to various complications affecting multiple organ systems, including diabetic retinopathy (eyes), diabetic nephropathy (kidneys), diabetic neuropathy (nerves), and cardiovascular diseases (heart disease and stroke). Uncontrolled diabetes can also lead to foot ulcers and lower limb amputations.[8,7]

Early diagnosis assumes critical significance in mitigating the risks and complications associated with diabetes. Detecting the condition early enables timely interventions and appropriate treatment plans. It empowers individuals to make necessary lifestyle modifications such as adopting healthy eating habits, engaging in regular physical activity, and effectively managing stress. Early diagnosis also enables healthcare professionals to closely monitor blood sugar levels and adjust medication or insulin regimens as required.[9-10]

This literature review aims to explore existing research on diabetes and its impact on individuals' lives. By examining current knowledge and evidence, we aim to gain insights into the latest advancements in early diagnosis techniques and their benefits in effectively managing diabetes. Through this review, we intend to contribute to the existing body of knowledge and raise awareness regarding the significance of early detection in enhancing diabetes care.

2. DIABETES SYMPTOMS AND RECOGNITION

The clinical manifestations of diabetes exhibit variability contingent upon the specific type and severity of the ailment. Typical symptoms encompass heightened frequency of urination, augmented thirst, unaccounted-for reduction in body mass, incessant feelings of hunger, fatigue, compromised visual acuity, sluggish wound healing, and recurrent infections. These symptoms manifest as a consequence of surplus glucose within the circulatory system, precipitating dehydration, weight loss despite escalated appetite and insufficient provisioning of energy to the body's cellular constituents.[8,12]

2.1 The challenges of symptom-based diagnosis

The diagnostic process for diabetes based on symptoms can present challenges influenced by various factors. Primarily, specific individuals may manifest mild or non-specific symptoms, which can be inadvertently disregarded or ascribed to alternative etiologies. For instance, augmented thirst and frequent urination can be misconstrued as standard fluctuations in hydration levels or unrelated urinary tract infections. Consequently, this delay in symptom recognition may impede the timely pursuit of medical intervention and subsequent diagnostic assessment..[1,11,13]

Secondly, the symptoms of diabetes may develop gradually over time, making them less noticeable or easily dismissed. This is especially true for type 2 diabetes, which often goes undiagnosed for years before being detected. As a result, individuals may live with untreated diabetes and unknowingly expose themselves to the risk of complications.[11]

Furthermore, certain groups may exhibit atypical symptoms or have a higher threshold for perceiving symptoms. For instance, older adults may experience fewer typical symptoms and instead present with complications such as cardiovascular disease or cognitive decline. This can lead to misdiagnosis or delayed diagnosis of diabetes.[14]

3. SCREENING APPROACHES FOR DIABETES DIAGNOSIS

3.1. Fasting Plasma Glucose (FPG) Test

An overnight fast is required for the Fasting Plasma Glucose (FPG) test, a standard screening procedure for diabetes, in order to measure blood glucose levels. The American Diabetes Association (ADA) recommends that a diagnosis of diabetes be made when two independent fasting plasma glucose levels are equal to or higher than 126 mg/dL (7 mmol/L).[15]

The accessibility and simplicity of the Fasting Plasma Glucose (FPG) test, which needs an overnight fast without any additional preparation, are two of its many noteworthy benefits. The fact that conditions like impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), which stand in between normal blood sugar levels and diabetes, may not be picked up by the Fasting Plasma Glucose (FPG) test must be acknowledged. The "white coat syndrome phenomenon," in which people have high blood sugar levels due to the stress of going to doctor's appointments, must also be considered. This can result in tests returning false-positive results.[16,17]

3.2. Oral Glucose Tolerance Test (OGTT)

An alternate method for identifying and diagnosing diabetes is the Oral Glucose Tolerance Test (OGTT). In this test, the subject consumes a standardized glucose solution, and blood glucose levels are checked before and two hours after the glucose load. Two hours after the glucose load, a blood glucose level of 200 mg/dL (11.1 mmol/L) or above indicates diabetes.[18]

The Oral Glucose Tolerance Test (OGTT) is more sensitive than the Fasting Plasma Glucose (FPG) test in identifying impaired glucose tolerance and the early stages of diabetes. It can successfully identify people with aberrant glucose metabolism who might not be detected by an FPG test alone. The OGTT necessitates a more significant time commitment and rigorous adherence to the prescribed standardized glucose load. The diagnostic technique may also cause some people to feel uncomfortable in their digestive system.[18,19]

3.3. Random Plasma Glucose Test

Although infrequently utilized, the Random Plasma Glucose test is a screening modality for individuals displaying clinical manifestations suggestive of hyperglycemia. This methodology continuously monitors blood glucose levels throughout the diurnal period, regardless of fasting status. The presence of polydipsia, polyuria, and a random plasma glucose level equal to or exceeding 200 mg/dL (11.1 mmol/L) can corroborate the diagnosis of diabetes.[20,21]

While the random plasma glucose test proves advantageous in promptly identifying symptomatic cases, it bears inherent limitations. Variations in blood glucose levels throughout the day may impact the accuracy of the test results, as timing plays a crucial role. Moreover, this diagnostic tool may fail to detect diabetes in asymptomatic individuals or those with mild hyperglycemia.[21]

3.4. HbA1c Test

The hemoglobin A1c (HbA1c) test, a diagnostic modality, evaluates an individual's mean blood glucose concentrations spanning two to three months. This comprehensive analysis yields valuable insights into the long-term management of glucose and represents a pivotal strategy for screening diabetes. By the guidelines set forth by the American Diabetes Association (ADA), a diagnosis of diabetes is established when the HbA1c level equals or surpasses 6.5%.[22,23]

The HbA1c test has several benefits, including convenience since there is no need to prepare by fasting. Additionally, glycemic control can be better monitored due to its long-term stability. A number of variables, including anemia, hemoglobinopathies, and certain medical conditions, might impact how accurate HbA1c tests are. Additionally, there may be differences in HbA1c readings between ethnic groups that must be considered.[22,23]

Comparative analysis of the effectiveness and limitations of each screening approach

Each screening approach has its own strengths and limitations in diagnosing diabetes.

1. The FPG test is convenient and widely available but may miss cases of impaired glucose metabolism.[24]
2. The OGTT is more sensitive in detecting early-stage diabetes but requires longer testing time and strict adherence to the glucose load.[25]
3. The random plasma glucose test is useful for diagnosing symptomatic individuals but may miss cases in asymptomatic individuals.[26]
4. The HbA1c test provides long-term glycemic control information but can be affected by certain medical conditions and variations among ethnic groups.

Diagnostic criteria and guidelines for diabetes screening

To standardize the diagnostic process, various organizations have established criteria and guidelines for diabetes screening.

1. The ADA recommends using any one of the following tests: FPG, OGTT, or HbA1c. They suggest repeating abnormal results on a different day to confirm the diagnosis.[27]
2. The World Health Organization (WHO) recommends using FPG or OGTT to diagnose diabetes.[28]
3. The International Expert Committee on Diabetes recommends adding HbA1c as a diagnostic tool if it is available.[29]

These guidelines help healthcare professionals in selecting the appropriate screening approach based on individual characteristics and resource availability.

4. ADVANCES IN DIABETES DIAGNOSIS TECHNOLOGIES

4.1. Continuous Glucose Monitoring (CGM)

Continuous Glucose Monitoring (CGM) represents an advanced technological solution that facilitates real-time monitoring of glucose levels throughout the diurnal cycle. This method entails the utilization of a diminutive sensor positioned beneath the dermis, which actively measures interstitial glucose concentrations and transmits the acquired data to a receiver or smartphone application. CGM furnishes comprehensive insights into glucose dynamics, encompassing fluctuations, trends, and patterns. Consequently, this technology equips individuals and healthcare practitioners with the requisite information to make well-informed decisions regarding diabetes management.[30]

The potential impact of CGM on the early detection and diagnosis of diabetes assumes considerable significance. CGM can detect anomalous glucose levels and trends even before the onset of symptomatic manifestations, thereby enabling timely intervention and the prevention of complications. Furthermore, by aiding in the identification of individuals exhibiting impaired glucose tolerance or prediabetic states, CGM facilitates the expeditious implementation of lifestyle modifications aimed at forestalling or delaying the onset of diabetes.[31]

4.2. Point-of-Care Testing (POCT)

Point-of-care testing (POCT) refers to a wide range of diagnostic procedures that can be performed directly at the location of patient care, such as a doctor’s office or primary care facility. These tests yield immediate results, eliminating the need to send samples to a central laboratory for analysis. Portable glucometers and HbA1c analyzers are examples of POCT equipment commonly used for diabetes diagnosis.[32]

POCT has excellent potential for early detection and diagnosis, mainly because it is available and straightforward. Using POCT, medical professionals can quickly and accurately get test findings, facilitating quick diagnosis and early execution of therapeutic actions. This benefit is precious in distant or underdeveloped locations with little access to lab resources. Additionally, POCT enables more frequent monitoring, making it easier to promptly modify diabetes care techniques to consider the disease's dynamic nature.[32,33]

4.3. Artificial Intelligence (AI) and Machine Learning

Machine learning (ML) and artificial intelligence (AI) applications have become a potent method for diagnosing diabetes. These cutting-edge technologies can analyze large volumes of patient data, such as medical records, test results, and genetic profiles. AI and ML significantly advance diagnostic efforts by spotting underlying trends and forecasting the likelihood of diabetes. They also assist in locating particular biomarkers or genetic markers closely linked to diabetes, enabling early detection and the creation of specialized treatment regimens.[34,35]

It is incredible how AI and ML may affect the early detection and diagnosis of diabetes. By enhancing risk prediction models, these cutting-edge technologies should enable tailored screening programs for people more likely to develop diabetes. Furthermore, integrating various data sources and offering decision-support features that improve diagnostic accuracy are useful tools for healthcare providers. By lowering human error and raising overall diagnostic accuracy, using AI-driven algorithms enhances the interpretation of diagnostic tests.[35,36]

4.4. Wearable Devices and Biosensors

The management of diabetes has undergone a substantial change due to recent advancements in biosensors and wearable technology, which now provide a more comprehensive range of therapeutic options. These cutting-edge gadgets can monitor various physiological parameters, including blood sugar levels, heart rate, activity levels, sleep patterns, and more. These tools continuously collect data to assess a person's overall health, enabling more precise and individualized treatment plans.[37,38] The potential impact of wearable devices and biosensors on early detection and diagnosis stems from their capacity to capture real-time data concerning glucose levels and other pertinent health parameters. Such devices proffer valuable insights into an individual's daily routines, behaviors, and responses to various interventions. This wealth of information holds the potential to flag early indications of diabetes or fluctuations in glucose levels that may warrant further scrutiny.[38]

Advancements in diagnostic technologies hold considerable promise for transforming the landscape of diabetes diagnosis. Innovative approaches, including Continuous Glucose Monitoring (CGM), Point-of-Care Testing (POCT), Artificial Intelligence (AI), Machine Learning, and wearable devices, present novel avenues for the early detection and personalized management of diabetes. These breakthroughs not only enhance precision, accessibility, and convenience but also augment data analysis capabilities, thereby facilitating timelier interventions and yielding improved outcomes for individuals affected by diabetes.[39,40]

As these diagnostic technologies continue to progress, ensuring their seamless integration into clinical practice is imperative. This necessitates addressing potential challenges such as cost-effectiveness and data privacy concerns. Furthermore, further research efforts are imperative to validate the effectiveness of these technologies across diverse populations. By embracing ongoing advancements in diagnostic technologies, we can anticipate enhanced early detection methodologies, superior management strategies, and ultimately, a positive transformative impact on the lives of individuals grappling with diabetes.[41,42]

5. Role of Machine Learning and Artificial Intelligence in Diabetes Diagnosis

Machine Learning (ML) and Artificial Intelligence (AI) methodologies have garnered substantial interest within the healthcare domain, with applications extending to diabetes diagnosis. Through the utilization of ML and AI algorithms, copious datasets can be scrutinized, facilitating the identification of patterns and enabling predictions that contribute to early detection and precise diagnosis of diabetes. The primary objective of this article is to furnish a comprehensive overview of the employment of ML and AI techniques in the realm of diabetes diagnosis. Moreover, we aim to conduct an in-depth analysis of pertinent studies investigating the accuracy and efficacy of these techniques.[35,43]

5.1 Overview of ML and AI techniques in diabetes diagnosis

5.1.1 Risk prediction models

Machine Learning (ML) and Artificial Intelligence (AI) algorithms can scrutinize an array of risk factors encompassing demographic information, medical history, and lifestyle factors, thereby enabling the prediction of an individual's susceptibility to be developing diabetes. These advanced models exhibit the capacity to simultaneously account for multiple variables, consequently facilitating a more precise risk assessment compared to conventional risk calculators. By identifying individuals at heightened risk, ML and AI algorithms facilitate targeted screening initiatives and the implementation of preventive interventions to mitigate the potential onset of diabetes.[43,44]

5.1.2 Diagnostic tools

Machine Learning (ML) and Artificial Intelligence (AI) algorithms possess the capacity to analyze comprehensive patient data, encompassing medical records, laboratory outcomes, and imaging studies, thereby serving as valuable aids in diagnosing diabetes. These sophisticated algorithms acquire knowledge from extensive datasets, recognizing patterns that can assist healthcare professionals in rendering precise diagnoses. By integrating diverse sources of data and furnishing decision support tools, ML and AI algorithms enhance diagnostic accuracy while mitigating the potential for human error.[45]

5.1.3 Image analysis

Machine Learning (ML) and Artificial Intelligence (AI) methodologies can be effectively employed in analyzing medical imaging data, encompassing retinal images or ultrasound scans, to identify complications associated with diabetes. A prominent illustration involves ML algorithms that can scrutinize retinal images, thereby facilitating the identification of indicative markers pertaining to diabetic retinopathy, a prevalent complication that arises from diabetes. This automated analysis of medical images significantly enhances the efficiency of screening initiatives, thus enabling timely intervention and facilitating expeditious treatment modalities.[46]

6. Challenges and Future Directions in Diabetes Diagnosis

The progress achieved in diagnostic technologies and the integration of Machine Learning (ML) and Artificial Intelligence (AI) techniques has undoubtedly enhanced the landscape of diabetes diagnosis. However, the field encounters several challenges that necessitate careful consideration. This article identifies and thoroughly examines the prevailing challenges encountered in diabetes diagnosis. Moreover, we will delve into potential solutions and outline future directions to augment screening initiatives and refine diagnostic practices surrounding diabetes.[43]

6.1 Challenges in Diabetes Diagnosis

6.1.1 Variability in Symptoms and Presentation

The clinical presentation of diabetes encompasses a diverse spectrum of symptoms, while its initial stages may manifest without identifiable symptoms. This variability poses a formidable challenge when attempting to rely solely on symptomatic manifestations for precise diagnosis. Furthermore, the symptomatology of diabetes may overlap with other medical conditions, potentially contributing to misdiagnosis or delayed recognition of the underlying condition.[13]

6.1.2 Access to Healthcare and Diagnostic Resources

Restricted availability of healthcare facilities, particularly in rural or underserved regions, poses a significant obstacle to achieving timely diagnoses. Inadequate access to essential diagnostic resources, including laboratory tests, imaging facilities, and specialized healthcare professionals, can impede the diagnostic process, resulting in delays and potentially compromising the accuracy of screenings.[47]

6.1.3 Ethnic and Genetic Variations

Certain ethnic groups have a higher risk of developing diabetes or exhibit different clinical manifestations. Genetic variations may also influence diabetes susceptibility and response to treatment. These factors pose challenges in developing universally applicable diagnostic criteria and algorithms.[48]

6.1.4 Data Quality and Standardization:

The accuracy and reliability of diagnostic tests and patient data play a crucial role in the accuracy of diabetes diagnosis. Variations in data collection methods, laboratory techniques, and data quality across different healthcare settings can affect the consistency of diagnoses.[49]

6.2 Potential Solutions and Future Directions

6.2.1 Enhanced Education and Awareness

Increasing awareness about diabetes symptoms, risk factors, and the importance of early diagnosis among healthcare professionals and the general population can promote early detection. Education programs can also focus on training healthcare professionals on the latest diagnostic guidelines and advancements.[50]

6.2.2 Improved Access to Healthcare

Efforts should be made to improve access to healthcare facilities, especially in underserved areas. Telemedicine and mobile health technologies can provide remote access to diagnostic consultations and screenings. Collaborations between healthcare providers, government agencies, and non-profit organizations can help bridge the gap in healthcare access.[51]

6.2.3 Development of Ethnic-Specific Algorithms

Considering ethnic and genetic variations in diabetes diagnosis algorithms can improve accuracy across diverse populations. Research studies focusing on specific ethnic groups can help identify unique risk factors, clinical presentations, and biomarkers for diabetes diagnosis within those populations.[52]

6.2.4 Data Sharing and Standardization

Promoting data sharing among healthcare institutions can improve the quality and standardization of diagnostic data. Collaboration between researchers, healthcare providers, and policymakers can establish guidelines for data collection, sharing, and analysis to enhance diagnostic accuracy.[53]

6.2.5 Integration of ML/AI in Routine Clinical Practice

Integrating ML/AI algorithms into routine clinical practice can assist healthcare professionals in accurate diagnosis, risk prediction, and personalized treatment plans. Continued research and development of ML/AI models should focus on their validation in real-world clinical settings and addressing issues related to interpretability, bias, and data privacy.[54]

6.2.6 Longitudinal Monitoring

Implementing longitudinal monitoring strategies is paramount in fostering the early detection and prevention of complications associated with diabetes. Emerging technologies such as continuous glucose monitoring (CGM) devices, wearable sensors, and remote monitoring technologies offer real-time data collection capabilities. By leveraging these advancements, healthcare professionals gain valuable insights into fluctuations in glucose levels, discern trends, and enable timely interventions to mitigate potential complications.[30]

7. CONCLUSION AND FINDINGS

In conclusion, the comprehensive review of the literature sheds light on several pivotal findings pertaining to the diagnosis of diabetes. The early detection of diabetes is paramount in facilitating effective management and prevention of associated complications. Nevertheless, the reliance on symptoms alone for diagnosis poses considerable challenges due to their inherent variability and nonspecific nature.

The emergence of advanced diagnostic technologies, encompassing Continuous Glucose Monitoring (CGM), Point-of-Care Testing (POCT), Artificial Intelligence (AI), Machine Learning (ML), and wearable devices, presents promising avenues for enhancing the accuracy and efficacy of diabetes diagnosis. These technologies offer real-time monitoring capabilities, augment diagnostic precision, fortify risk prediction models, and enable the identification of diabetes-related complications.

Studies evaluating the accuracy and efficiency of ML and AI methodologies demonstrate their potential in predicting the onset of diabetes, refining diagnostic accuracy, and enhancing screening efforts for complications such as diabetic retinopathy. However, further research endeavors are necessary to validate these methodologies within real-world clinical settings, address data privacy and algorithm interpretability challenges, and evaluate their generalizability across diverse populations.

The implications for healthcare professionals are profound. They must remain abreast of advancements in diagnostic technologies and adhere to established guidelines for diabetes screening. Integrating these innovative technologies into routine clinical practice can significantly enhance diagnostic accuracy, facilitate timely interventions, and promote the adoption of personalized treatment approaches.

Future research endeavors should prioritize the development of ethnicity-specific algorithms, advocate for data sharing and standardization, and facilitate the seamless integration of ML/AI algorithms into routine clinical practice. Furthermore, longitudinal monitoring strategies utilizing CGM devices and wearable sensors hold promise in facilitating the early detection of diabetes and preventing associated complications.

In conclusion, the comprehensive literature review underscores the criticality of early detection in managing diabetes while highlighting the potential of advanced diagnostic technologies, ML, and AI in improving screening accuracy. By embracing these advancements and addressing existing research gaps, healthcare professionals can enhance their diagnostic capabilities and ultimately improve outcomes for individuals living with diabetes.

7. REFERENCES

1. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013; 36 Suppl 1(Suppl 1): S67-74.
2. Dilworth L, Facey A, Omoruyi F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. International Journal of Molecular Sciences, 2021; 22(14): 7644.
3. Solis-Herrera C, Triplitt C, Reasner C, DeFronzo RA, Cersosimo E. Classification of diabetes mellitus, 2015.
4. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci., 2020; 21(17).
5. Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes, 2021; 14: 3567-602.
6. Verma AK, Goyal Y, Bhatt D, Dev K, Alsahli MA, Rahmani AH, et al. A Compendium of Perspectives on Diabetes: A Challenge for Sustainable Health in the Modern Era. Diabetes Metab Syndr Obes, 2021; 14: 2775-87.

7. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med, 2015; 32(4): 459-66.
8. Phrommintikul A, Dilokthornsakul P, Permsuwan U. Economic Burdens for Treatment of Patients With Type 2 Diabetes in North Thailand: A Hospital-Based Observational Study. Front Endocrinol (Lausanne), 2022; 13: 824545.
9. Mohammed AA, Barale SS, Kamble SA, Paymal SB, Sonawane KD. Molecular insights into the inhibition of early stages of Aβ peptide aggregation and destabilization of Alzheimer's Aβ protofibril by dipeptide D-Trp-Aib: A molecular modelling approach. International Journal of Biological Macromolecules, 2023; 242: 124880.
10. Adu MD, Malabu UH, Malau-Aduli AEO, Malau-Aduli BS. Enablers and barriers to effective diabetes self-management: A multi-national investigation. PLoS One, 2019; 14(6): e0217771.
11. Ramachandran A. Know the signs and symptoms of diabetes. Indian J Med Res., 2014; 140(5): 579-81.
12. Goyal R, Jialal I. Diabetes mellitus type 2. 2018.
13. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2011; 34 Suppl 1(Suppl 1): S62-9.
14. McSweeney J, Pettey C, Lefler LL, Heo S. Disparities in heart failure and other cardiovascular diseases among women. Womens Health (Lond), 2012; 8(4): 473-85.
15. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010; 375(9733): 2215-22.
16. Janghorbani M, Amini M. Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan Diabetes Prevention Study. Rev Diabet Stud, 2011; 8(4): 490-8.
17. Pioli MR, Ritter AM, de Faria AP, Modolo R. White coat syndrome and its variations: differences and clinical impact. Integr Blood Press Control, 2018; 11: 73-9.
18. Eyth E, Basit H, Smith CJ. Glucose tolerance test, 2018.
19. Lages M, Barros R, Moreira P, Guarino MP. Metabolic Effects of an Oral Glucose Tolerance Test Compared to the Mixed Meal Tolerance Tests: A Narrative Review. Nutrients, 2022; 14(10).
20. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care, 2018; 41(9): 2026-44.
21. Mathew TK, Tadi P. Blood glucose monitoring, 2020.
22. Eyth E, Naik R. Hemoglobin A1c, 2019.
23. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights, 2016; 11: 95-104.
24. Aekplakorn W, Tantayotai V, Numsangkul S, Sripho W, Tatsato N, Burapasiriwat T, et al. Detecting Prediabetes and Diabetes: Agreement between Fasting Plasma Glucose and Oral Glucose Tolerance Test in Thai Adults. J Diabetes Res. 2015; 2015: 396505.
25. De Sanctis V, Soliman A, Daar S, Tzoulis P, Di Maio S, Kattamis C. Oral glucose tolerance test: How to maximize its diagnostic value in children and adolescents. Acta Biomed, 2022; 93(5): e2022318.
26. Agbozo F, Abubakari A, Narh C, Jahn A. Accuracy of glycosuria, random blood glucose and risk factors as selective screening tools for gestational diabetes mellitus in comparison with universal diagnosing. BMJ Open Diabetes Res Care, 2018; 6(1): e000493.

27. Committee ADAPP. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2021; 45(Supplement_1): S17-S38.
28. Adam JM, Tarigan NP. Comparison of The World Health Organization (WHO) two-step strategy and OGTT for diabetes mellitus screening. Acta Med Indones, 2004; 36(1): 3-7.
29. Florkowski C. HbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the Evidence. Clin Biochem Rev, 2013; 34(2): 75-83.
30. Reddy N, Verma N, Dungan K. Monitoring technologies-continuous glucose monitoring, mobile technology, biomarkers of glycemic control. Endotext [Internet], 2020.
31. Soliman A, DeSanctis V, Yassin M, Elalaily R, Eldarsy NE. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab, 2014; 18(3): 274-82.
32. Larkins MC, Thombare A. Point-of-Care Testing. StatPearls [Internet]: StatPearls Publishing, 2023.
33. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis, 2014; 14(3): 239-49.
34. Agliata A, Giordano D, Bardozzo F, Bottiglieri S, Facchiano A, Tagliaferri R. Machine Learning as a Support for the Diagnosis of Type 2 Diabetes. Int J Mol Sci, 2023; 24(7).
35. Singla R, Singla A, Gupta Y, Kalra S. Artificial Intelligence/Machine Learning in Diabetes Care. Indian J Endocrinol Metab, 2019; 23(4): 495-7.
36. Nomura A, Noguchi M, Kometani M, Furukawa K, Yoneda T. Artificial Intelligence in Current Diabetes Management and Prediction. Curr Diab Rep, 2021; 21(12): 61.
37. Psoma SD, Kanthou C. Wearable Insulin Biosensors for Diabetes Management: Advances and Challenges. Biosensors, 2023; 13(7): 719.
38. Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, et al. Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus, 2023; 15(8): e43697.
39. Rickson M, Wright EE, Jr., Bindal A, Ghonim L. Advancements in Diabetes Technology Are Outpacing the Evidence. Diabetes Technol Ther, 2023; 25(S3): S35-s41.
40. Makroum MA, Adda M, Bouzouane A, Ibrahim H. Machine Learning and Smart Devices for Diabetes Management: Systematic Review. Sensors (Basel), 2022; 22(5).
41. Junaid SB, Imam AA, Balogun AO, De Silva LC, Surakat YA, Kumar G, et al. Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey. Healthcare (Basel), 2022; 10(10).
42. Abernethy A, Adams L, Barrett M, Bechtel C, Brennan P, Butte A, et al. The Promise of Digital Health: Then, Now, and the Future. NAM Perspect, 2022; 2022.
43. Nguyen LP, Tung DD, Nguyen DT, Le HN, Tran TQ, Binh TV, et al. The Utilization of Machine Learning Algorithms for Assisting Physicians in the Diagnosis of Diabetes. Diagnostics (Basel), 2023; 13(12).
44. Gosak L, Martinović K, Lorber M, Stiglic G. Artificial intelligence based prediction models for individuals at risk of multiple diabetic complications: A systematic review of the literature. J Nurs Manag, 2022; 30(8): 3765-76.
45. Kumar Y, Koul A, Singla R, Ijaz MF. Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. J Ambient Intell Humaniz Comput, 2023; 14(7): 8459-86.
46. Barragán-Montero A, Javaid U, Valdés G, Nguyen D, Desbordes P, Macq B, et al. Artificial intelligence and machine learning for medical imaging: A technology review. Phys Med, 2021; 83: 242-56.

47. Aderinto N, Olatunji D, Abdulbasit M, Edun M. The essential role of neuroimaging in diagnosing and managing cerebrovascular disease in Africa: a review. Ann Med, 2023; 55(2): 2251490.
48. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep, 2013; 13(6): 814-23.
49. Adane K, Gizachew M, Kendie S. The role of medical data in efficient patient care delivery: a review. Risk Manag Healthc Policy, 2019; 12: 67-73.
50. Nazar CM, Bojerenu MM, Safdar M, Marwat J. Effectiveness of diabetes education and awareness of diabetes mellitus in combating diabetes in the United Kigdom; a literature review. J Nephropharmacol, 2016; 5(2): 110-5.
51. Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: Capabilities, features, barriers, and applications. Sens Int, 2021; 2: 100117.
52. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care, 2023; 46(Suppl 1): S19-s40.
53. Hulsen T. Sharing Is Caring-Data Sharing Initiatives in Healthcare. Int J Environ Res Public Health, 2020; 17(9).
54. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education, 2023; 23(1): 689.